Advanced Biomed Inc.

Advanced Biomed Inc. has filed its Definitive Proxy Statement for the Annual Meeting of Stockholders scheduled for June 30, 2026. Key agenda items include the election of five directors, an advisory vote on executive compensation, determining the frequency of future advisory votes on executive compensation, and ratifying WWC, P.C. as the independent auditor. The company also announced a recent leadership transition with Xiaomin Chen becoming Chairman and CEO and the acquisition of Acellent Technologies (Hong Kong) Co. Limited. The Board of Directors recommends favorable votes on all proposals.

Advanced Biomed Inc. reported a net income of $5.98 million for the nine months ended March 31, 2026, primarily driven by a $7.35 million gain from the divestment of its Hong Kong subsidiary. However, the company posted a net loss of $488,942 for the three-month period. Despite the nine-month profit, the company continues to face substantial doubt about its ability to continue as a going concern due to ongoing operating cash outflows.

Advanced Biomed Inc. announced a significant strategic pivot, shifting its primary business focus from life sciences to artificial intelligence development. Concurrently, the company completed the acquisition of Acellent Technologies (Hong Kong) Co. Limited for $1,080,000, paid in 270,000 shares of common stock. In line with this strategic change, Mr. Yi Lu mutually separated from his roles as CEO and Chairman, receiving 39,999 shares as severance. Mr. Xiaomin Chen, the former CEO of Acellent Technologies and an AI expert, was appointed as the new CEO, director, and Chairman, effective April 28, 2026, with a monthly salary of $12,000.

Advanced Biomed Inc. entered into a Loan Agreement on April 13, 2026, securing an unsecured loan of $600,000 from Jie Wang. The loan bears an annual interest rate of 10% and has a six-month term, which can be extended for an additional six months by mutual agreement. The company intends to use the loan proceeds to support its ongoing operations.